VIENNA, Va., Nov. 10 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM), a drug development company with its lead cancer product
cleared for a Phase III trial in Canada, announced that its Chief Executive
Officer, Geert Kersten, is a featured presenter at the Life Science
Informed Investors On-line Forum. The webcast presentation is scheduled for
Tuesday, November 14, 2006 at 11:00 a.m. (Eastern Daylight Time) and can be
accessed via the Internet at http://www.informedinvestors.com.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine(R)
is cleared to enter global Phase III clinical trials in advanced primary
head and neck cancer patients. CEL-SCI's other products, which are
currently in pre- clinical stage and are funded with U.S. government
support, have shown protection against a number of diseases in animal tests
and are being tested against diseases associated with bio-defense and avian
flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com//
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
